1. Home
  2. HURA vs FSI Comparison

HURA vs FSI Comparison

Compare HURA & FSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • FSI
  • Stock Information
  • Founded
  • HURA 2009
  • FSI 1991
  • Country
  • HURA United States
  • FSI Canada
  • Employees
  • HURA N/A
  • FSI N/A
  • Industry
  • HURA
  • FSI Recreational Games/Products/Toys
  • Sector
  • HURA
  • FSI Consumer Discretionary
  • Exchange
  • HURA Nasdaq
  • FSI Nasdaq
  • Market Cap
  • HURA 126.1M
  • FSI 120.2M
  • IPO Year
  • HURA N/A
  • FSI 1999
  • Fundamental
  • Price
  • HURA $2.59
  • FSI $9.00
  • Analyst Decision
  • HURA Strong Buy
  • FSI
  • Analyst Count
  • HURA 2
  • FSI 0
  • Target Price
  • HURA $11.50
  • FSI N/A
  • AVG Volume (30 Days)
  • HURA 214.3K
  • FSI 68.8K
  • Earning Date
  • HURA 11-13-2025
  • FSI 11-13-2025
  • Dividend Yield
  • HURA N/A
  • FSI 1.13%
  • EPS Growth
  • HURA N/A
  • FSI 5.17
  • EPS
  • HURA N/A
  • FSI 0.23
  • Revenue
  • HURA N/A
  • FSI $37,322,073.00
  • Revenue This Year
  • HURA N/A
  • FSI $11.26
  • Revenue Next Year
  • HURA N/A
  • FSI $52.79
  • P/E Ratio
  • HURA N/A
  • FSI $38.40
  • Revenue Growth
  • HURA N/A
  • FSI N/A
  • 52 Week Low
  • HURA $1.80
  • FSI $3.31
  • 52 Week High
  • HURA $8.40
  • FSI $11.48
  • Technical
  • Relative Strength Index (RSI)
  • HURA 45.68
  • FSI 45.50
  • Support Level
  • HURA $2.38
  • FSI $8.75
  • Resistance Level
  • HURA $2.66
  • FSI $10.50
  • Average True Range (ATR)
  • HURA 0.12
  • FSI 0.68
  • MACD
  • HURA 0.01
  • FSI -0.24
  • Stochastic Oscillator
  • HURA 42.86
  • FSI 1.57

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About FSI Flexible Solutions International Inc. (CDA)

Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The firm also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.

Share on Social Networks: